XORTX Therapeutics (TSXV:XRTX) EV-to-EBIT : -0.72 (As of May. 04, 2024)

View and export this data going back to 2015. Start your Free Trial

What is XORTX Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, XORTX Therapeutics's Enterprise Value is C$5.88 Mil. XORTX Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was C$-8.16 Mil. Therefore, XORTX Therapeutics's EV-to-EBIT for today is -0.72.

The historical rank and industry rank for XORTX Therapeutics's EV-to-EBIT or its related term are showing as below:

TSXV:XRTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -52.04 Med: 0 Max: 1.04
Current: -0.72

During the past 9 years, the highest EV-to-EBIT of XORTX Therapeutics was 1.04. The lowest was -52.04. And the median was 0.00.

TSXV:XRTX's EV-to-EBIT is ranked worse than
100% of 434 companies
in the Biotechnology industry
Industry Median: 8.915 vs TSXV:XRTX: -0.72

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. XORTX Therapeutics's Enterprise Value for the quarter that ended in Sep. 2023 was C$7.21 Mil. XORTX Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was C$-8.16 Mil. XORTX Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -113.08%.

XORTX Therapeutics EV-to-EBIT Historical Data

The historical data trend for XORTX Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics EV-to-EBIT Chart

XORTX Therapeutics Annual Data

Trend

Feb15

Feb16

Feb17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-16.85

-9.08

-8.20

-0.29

-0.15

XORTX Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-0.29	-0.10	-1.12	-1.21	-

Competitive Comparison of XORTX Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, XORTX Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XORTX Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where XORTX Therapeutics's EV-to-EBIT falls into.

XORTX Therapeutics EV-to-EBIT Calculation

XORTX Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	5.883	/	-8.155
	=	-0.72

XORTX Therapeutics's current Enterprise Value is C$5.88 Mil.
XORTX Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-8.16 Mil.

XORTX Therapeutics (TSXV:XRTX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

XORTX Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 )	=	EBIT	/	Enterprise Value (Q: Sep. 2023 )
	=	-8.155	/	7.211927
	=	-113.08 %

XORTX Therapeutics's Enterprise Value for the quarter that ended in Sep. 2023 was C$7.21 Mil.
XORTX Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-8.16 Mil.

XORTX Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

XORTX Therapeutics (TSXV:XRTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (TSXV:XRTX) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

XRTX:USA ANUA:Germany ANUA:Germany

Address

3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1

Website

https://www.xortx.com

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.